You are here

Bioiberica successfully passed an unannounced inspection by the FDA

28 May 2013

Last May Bioiberica had a non scheduled inspection from the US FDA in its facility in Geneva (Nebraska) where the first steps of heparin sodium production are performed.

Bioiberica is pleased to announce that this three days inspection finished with no deviations.
Once again, Bioiberica was able to demonstrate its extremely high quality level, a key factor to keep its worldwide leading position as heparin sodium manufacturer.

Related News

23 May 2024

A crucial initiative to prevent shortages of critical medicines in the European Union.

28 Sep 2021

The 28th Symposium on Glycosaminoglycans, an internationally renowned scientific event focusing on glycosaminoglycans, will be sponsored by

4 Aug 2021
  • Bioiberica produces 20% of the world's Heparin API.
  • Heparin saves around a hundred million lives every year.
  • One out of every 5 doses of heparin administered in the world comes from Bioiberica.